^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Marginal Zone Lymphoma
    Regimen:R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    01/06/2020
    Excerpt:
    Table 6: Summary of recommendations: EMZL- Other treatments including ChT, immunotherapy or combination chemoimmunotherapy are indicated in patients with symptomatic disseminated disease, contraindications to RT, failure after antibiotics or after local therapy or clinical suspicion of histological transformation:...R-CHOP for (clinically suspected or biopsy-proven) histological transformation....Chemoimmunotherapy is recommended in patients with NMZL (e.g. R-bendamustine, R-CHOP, R-CVP) [IV, B].
    DOI:
    10.1016/j.annonc.2019.10.010
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Marginal Zone Lymphoma: Second-Line and subsequent therapy...CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + Rituximab